InsidersTradesSigma
Track the Pacira BioSciences, Inc. share price and the full directors' dealings record of the company, a listed equity based in United States. Shares trade on the US market, under the oversight of SEC (Form 4). Operating in the Healthcare & Pharma sector, Pacira BioSciences, Inc. has logged 216 insider filings. Market capitalisation: €924m. The latest transaction was disclosed on 18 August 2026 (Cession). Among the most active insiders: SLONIN JONATHAN. The full history is free.
216
Insider Decl.
n/a
Thresholds
€234,293
7 ops.
Buy Volume
€6m
61 ops.
Sell Volume
Analyst consensus: bullish or bearish?
Analysts rate Pacira BioSciences, Inc. Buy (bullish), based on 6 analysts. Average price target: US$30.00.
35Σ signal
This score ranks the purchase within its own market. No market currently meets the historical allocation criteria, so signals remain watch-only. Not investment advice.
Fundamental score
Ranked 23,117 of 29,062 companies
31.0
score / 100
Value24
Quality38
FCF yld-3.8%
Earn yld-4.8%
EV/EBITDA·
ROE-40%
Gross mgn93%
Net mgn-18%
Debt/EBITDA·
Pillars2/3
Transparent value + quality ranking, distinct from the insider signal.
Sigma AI Analysis
Fundamental view, insider signal, bull and bear case, synthesis.
AI analysis generation is paused.
Last declaration on 18 August 2026
Declarations216 total
3,040 shares@ US$23.23Common StockSEC:0001628280-26-057759:0
3,040 shares@ US$23.230.0076% mcap7.2% of flowCommonSEC144:0001959173-26-006073
9,039 shares@ US$23.2740.021% mcap76.8% of flowCommonSEC144:0001959173-26-004600
6,405 sharesCommon StockSEC:0001628280-26-043004:0
6,405 sharesCommon StockSEC:0001628280-26-043002:0
6,405 sharesCommon StockSEC:0001628280-26-043008:0
6,115 shares@ US$23.500.014% mcap39.7% of flowCommonSEC144:0001959173-26-004550
10,259 shares@ US$22.270.022% mcap27.4% of flowCommonSEC144:0001959173-26-004324
12,941 shares@ US$16.450.021% mcap39.5% of flowCommon StockSEC:0001628280-26-027287:0
12,941 shares@ US$25.160.032% mcap60.5% of flowCommon StockSEC:0001628280-26-027287:1
7,714 shares@ US$16.450.012% mcap12.1% of flowCommon StockSEC:0001628280-26-026669:0
7,714 shares@ US$25.140.019% mcap18.6% of flowCommon StockSEC:0001628280-26-026669:1
2,845 shares@ US$16.450.0045% mcap4.5% of flowCommon StockSEC:0001628280-26-026669:2
2,845 shares@ US$25.010.0069% mcap6.8% of flowCommon StockSEC:0001628280-26-026669:3
1,500 shares@ US$16.450.0024% mcap2.4% of flowCommon StockSEC:0001628280-26-026669:4
1,500 shares@ US$25.010.0037% mcap3.6% of flowCommon StockSEC:0001628280-26-026669:5
6,163 shares0Common StockSEC:0001628280-26-019892:0
500 shares@ US$21.8111.8% of flowCommon StockSEC:0001628280-26-019890:0
3,261 shares@ US$22.8210.9% of flowCommon StockSEC:0001628280-26-019891:0
49,091 shares0Common StockSEC:0001628280-26-008080:0
54,546 shares0Common StockSEC:0001628280-26-008078:0
51,714 shares0Common StockSEC:0001628280-26-008077:0
19,273 shares0Common StockSEC:0001628280-26-008076:0
54,546 shares0Common StockSEC:0001628280-26-008075:0
261,818 shares0Common StockSEC:0001628280-26-008074:0
25 of 216 declarations
关于 Pacira BioSciences, Inc.
Pacira BioSciences, Inc.是一家在美国纳斯达克（美国）上市的美国生物制药公司，专注于非阿片类疼痛管理。该公司的商业平台围绕主要用于医院和门诊环境的注射疗法和冷冻神经溶解解决方案构建。Pacira的核心特许经营权是EXPAREL，其脂质体布比卡因产品，长期以来一直是公司主要收入驱动力。通过2019年收购iovera°和ZILRETTA（一种缓释曲安奈德注射混悬液），产品组合得到了拓宽。从战略上讲，Pacira将自己定位为减少围手术期护理和特定骨科疼痛适应症中对阿片类药物依赖的领导者。([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-completes-acquisition-myoscience-advancing-leadership-non)) 公司总部位于加利福尼亚州布里斯班，使其处于美国主要的生命科学中心。其商业模式结合了直接商业化、产品收入生成以及不断扩大的许可和合作协议。2024年，Pacira报告的净产品销售额为697.2 million美元，其中EXPAREL领先，其次是ZILRETTA和iovera°。这种组合突显了集中但有意义的专业制药收入基础，少数品牌资产承担了大部分财务业绩。([sec.gov](https://www.sec.gov/Archives/edgar/data/1396814/000110465925041234/tm254483d2_ars.pdf)) 从竞争角度来看，Pacira的差异化在于其在非阿片类药物市场的定位，在该市场中，对阿片类药物替代疼痛解决方案的需求在美国仍然具有结构性重要性。EXPAREL由专有的DepoFoam递送技术支持，而iovera°提供靶向冷冻神经溶解以暂时中断疼痛信号。ZILRETTA增加了一种骨科导向的资产，与骨关节炎和相关疼痛管理相关。总而言之，这些产品使Pacira在专业治疗领域占据了利基领导地位，在该领域，临床应用、报销和差异化产品性能比广泛的初级保健规模更为重要。([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-completes-acquisition-myoscience-advancing-leadership-non)) 近期发展表明商业势头正在改善。在2025年第四季度，Pacira报告收入为196.9 million美元，EXPAREL销售额创历史新高，同时iovera°也实现了同比增长。2025年11月，公司宣布与AmacaThera签订了一项关于AMT-143（一种用于术后疼痛的长效罗哌卡因制剂）的全球独家许可协议，表明持续的管线和业务发展活动。公司还继续进行股票回购，在运营执行的同时加强了资本配置重点。对于投资者而言，Pacira代表了一家在纳斯达克上市的美国医疗保健公司，受益于不断增长的非阿片类疼痛市场，但也面临着少数旗舰产品带来的集中风险。([investor.pacira.com](https://investor.pacira.com/news-releases/news-release-details/pacira-biosciences-reports-fourth-quarter-and-full-year-2025?utm_source=openai))
